Inaedis
Princeton, US · 2 known investors
Inaedis develops RTAD (Room Temperature Aerosol Dehydration), a cGMP-compatible technology that converts liquid biologic drugs and vaccines into room-temperature-stable powder and suspension formulations, enabling routes such as subcutaneous, inhaled, and intranasal delivery. It serves pharmaceutical, public health, and defense customers seeking cold-chain-free biologics and higher-concentration formulations, based on technology licensed from Princeton University.
BiotechDeep TechHealthtech
Investors · 2
.jpeg){kind=logo}
Frequently asked questions
- What does Inaedis do?
- Inaedis develops RTAD (Room Temperature Aerosol Dehydration), a cGMP-compatible technology that converts liquid biologic drugs and vaccines into room-temperature-stable powder and suspension formulations, enabling routes such as subcutaneous, inhaled, and intranasal delivery. It serves pharmaceutical, public health, and defense customers seeking cold-chain-free biologics and higher-concentration formulations, based on technology licensed from Princeton University.
- Who are Inaedis's investors?
- Inaedis's investors include New Jersey Economic Development Authority, Roadrunner Ventures.
- Where is Inaedis headquartered?
- Inaedis is headquartered in Princeton, US.